India, Oct. 19 -- Drug major Johnson & Johnson (JNJ) announced Monday positive one-year results from the Phase 3 FUZION study, which showed TREMFYA (guselkumab) maintained or improved fistula remission through 48 weeks in adults with inflammatory bowel disease Crohn's disease or CD.
According to the company, TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula.
Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract with no known cause, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition, diet, or other environmental factors.
JNJ-developed TREMFYA is the first ful...